Research programme: P2X receptor antagonists - Abbvie
Alternative Names: A-740003Latest Information Update: 04 Nov 2017
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Hydrazines; Tetrazoles
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation; Mood disorders; Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
- 04 Nov 2017 No recent reports of development identified for research development in Mood disorders in USA